Alexander Spira, MD, PhD, FACP

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    CytomX Therapeutics
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    AstraZeneca/MedImmune
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Merck
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Takeda
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Amgen
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Janssen Oncology
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Novartis
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Bristol-Myers Squibb
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Bayer
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    incyte
    Date added: 
    08/16/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond